Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21489868 | 0.85 | SMYD3 (0.57) | — | |
| SCHEMBL19701339 | 0.85 | SMYD3 (0.57) | — | |
| SCHEMBL2159094 | 0.83 | GRM5 (0.57) | GRM5NPC1RAB9AHPGDCYP1A2 | |
| SCHEMBL1969968 | 0.83 | GRM5 (0.57) | GRM5NPC1RAB9AHPGDCYP1A2 | |
| SCHEMBL5429264 | 0.83 | NPC1 (0.65) | GRM5NPC1RAB9AHPGDCYP1A2 | |
| SCHEMBL5429612 | 0.83 | NPC1 (0.65) | GRM5NPC1RAB9AHPGDCYP1A2 | |
| SCHEMBL5424850 | 0.81 | NPC1 (0.62) | GRM5NPC1RAB9AHPGDCYP1A2 | |
| SCHEMBL3244479 | 0.81 | ALDH1A1 (0.57) | GRM5NPC1RAB9AHPGDCYP1A2 | |
| SCHEMBL28928584 | 0.81 | NPC1 (0.82) | NPC1RAB9AHPGDCYP1A2CYP2C19 | |
| SCHEMBL520877 | 0.81 | NPC1 (0.82) | NPC1RAB9AHPGDCYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6544986-B2 | Such as 5-(N,N-dibenzyl)aminocarbonyl-2-pyridone; enzyme inhibitors; for treatment of Alzheimer's disease | DALHOUSIE UNIVERSITY (CA) | 2003-04-08 | — | — | US | disclosed |
| US-6436972-B1 | HETEROCYCLIC AMIDES, USED AS ANTICHOLINERGICS AND SERINE PROTEASE STIMULANTS, FOR PROPHYLAXIS OF ALZHEIMER'S DISEASE, GLIOMAS AND VISION DEFECTS | DALHOUSIE UNIVERSITY (CA) | 2002-08-20 | — | — | US | disclosed |
| US-20020049330-A1 | Novel pyridones and their use as modulators of serine hydrolase enzymes | DALHOUSIE UNIVERSITY | 2002-04-25 | — | — | US | disclosed |
| WO-2001077078-A1 | NOVEL PYRIDONES AND THEIR USE AS MODULATORS OF SERINE HYDROLASE ENZYMES | DALHOUSIE UNIVERSITY (CA) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049330-A1 | Novel pyridones and their use as modulators of serine hydrolase enzymes | BCHE, PRSS1, BACE1 | GRM5 1525/4885NPC1 2234/4885RAB9A 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.